Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00574795

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants

Vaccines, Pneumococcal Conjugate Vaccine Clinical Trial

Official title:
A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (13vPnC) in infants of Japanese descent.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

  • Vaccines, Pneumococcal Conjugate Vaccine
Clinical Trial Details
NCT number NCT00574795
Study type Interventional
Source Wyeth is now a wholly owned subsidiary of Pfizer
Contact
Status Completed
Phase Phase 3
Start date September 2007
Completion date August 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT00269672 - Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects Phase 2
Completed NCT00580684 - Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children Phase 4
Completed NCT00500357 - Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects Phase 3
Completed NCT00581620 - Study Evaluating Prevenar Immunogenicity in High Risk Children Phase 4
Completed NCT00475033 - Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Phase 3
Completed NCT00980655 - Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Phase 3
Completed NCT00676091 - Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil Phase 3
Completed NCT00683410 - Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent) N/A